ARTICLES BY LOUIS GARGUILO

• The Enlightened Battles Of Biopharma Outsourcing

  3/1/2016

  In drug development, the threat level is always immanent. Too often there’s no alternative to preparing a detailed map of a landscape that may not exist. “Outsourcing” is the inadequate label we’ve affixed to a potent weapon to more effectively wage winning campaigns. 

• Biopharma Outsourcing Past Is Prologue

  2/24/2016

  It seems the more things change, the more these three components – biopharma entrepreneurs, financial backers, and outsourcing service providers – need to work together. The past helps us see this future more clearly. 

• Innovators In The Pharmaceutical Packaging Industry

  12/11/2015

  As biologics and global injectable-drug markets grow, BioPharma needs advancements ensuring the highest quality in the integration of new delivery systems and packaging technologies that can be administered outside of clinical settings. Service providers are responding.

• Are There Enough Biomanufacturing Workers In The U.S.?

  10/14/2015

  Is there a sufficient supply of trained workers and students to fill biomanufacturing positions in the U.S.? I asked Kamal Rashid; he’s trained workers and students for companies such as Biogen, GE, Genzyme, Intel, and Lonza. He answered our question this way: “There should be.” Here’s why … 

• Pfizer Acquires Hospira: Biosimilars Gain Full Pharma Acceptance

  2/5/2015

  Just days after Outsourced Pharma’s in-depth, two-part article on Hospira and the role of biosimilars in global healthcare, and in which I asked Hospira’s Sumant Ramachandra whether he foresaw a future where a Pfizer comes to Hospira to work together on biosimilars, we have a definitive answer.

• Biosimilars Part 2: It’s All About Dollars Now

  2/2/2015

  Time to table the discussion on the science of replicating biologics. It’s all about dollars now. Part two of our look at biosimilars in the U.S.

• Biosimilars: A Brief Manifesto of Morality And Markets

  1/26/2015

  As best I can describe it, here's an ideology for biosimilars in the U.S. healthcare system, from Sumant Ramachandra, executive and scientist at Hospira, Inc.